Researchers at Cimplrx Co. Ltd. and Samjin Pharmaceutical Co. Ltd. have identified ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1) inhibitors ...

Completion of enrollment in the ENERGY 3 pivotal trial for INZ-701, a significant milestone in pediatric patients with ENPP1 Deficiency, with topline data expected in the first quarter of 2026.